Julie Waterbury
Psychiatric/Mental Health · Saint Louis, MONPI 1447552260
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $107,362 of the $135,112 with a category attached, or 79.5%. Neurocrine Biosciences, Inc. accounts for 94.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $60,632 and has fallen 96.9% since, to $1,865 in 2025. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $547.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$128K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Acadia Pharmaceuticals Inc$722
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$139
- plus $699 from 12 others
What the payments were for
- Consulting fees$10,8668%
- Speaking & faculty fees$107,36279%
- Travel & lodging$5,6264%
- Food & beverage$11,2328%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 148 | $128,259 |
| Alkermes, Inc. | 25 | $1,906 |
| Teva Pharmaceuticals USA, Inc. | 22 | $1,814 |
| E.r. Squibb & Sons, L.L.C. | 11 | $1,573 |
| Acadia Pharmaceuticals Inc | 23 | $722 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $139 |
| Luye Pharma (USA) Ltd. | 1 | $123 |
| Bioxcel Therapeutics, Inc. | 1 | $120 |
| Tris Pharma Inc | 1 | $119 |
| AbbVie | 5 | $103 |
| Indivior Inc. | 1 | $95 |
| Harmony Biosciences LLC | 1 | $36 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Almatica Pharma LLC | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$126,427
- LYBALVI$2,635
- ARISTADA$2,617
- AUSTEDO$842
- ARISTADA INITIO$715
- COBENFY$580
- UZEDY$360
- Austedo XR$247
- ERZOFRI EXTENDED-RELEASE$123
- IGALMI$120
- CAPLYTA$120
- Dyanavel XR$119
How this compares
$135,112 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 768 | $5,828,203 |
| NuplazidPimavanserin Tartrate | 84 | $273,601 |
| Invega SustennaPaliperidone Palmitate | 77 | $221,164 |
| UzedyRisperidone | 47 | $156,600 |
| RexultiBrexpiprazole | 164 | $119,409 |
| AristadaAripiprazole Lauroxil | 25 | $71,185 |
| Abilify MaintenaAripiprazole | 23 | $68,633 |
| VraylarCariprazine Hcl | 84 | $58,358 |
| Divalproex Sodium | 777 | $43,404 |
| TrintellixVortioxetine Hydrobromide | 131 | $41,255 |
| Lurasidone Hcl | 138 | $41,174 |
| PerserisRisperidone | 12 | $36,778 |
| SecuadoAsenapine | 20 | $29,447 |
| FanaptIloperidone | 27 | $29,428 |
| Risperdal ConstaRisperidone Microspheres | 15 | $26,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $128,259 | $5,828,203768 claims |
| Acadia Pharmaceuticals IncNuplazid | $722 | $273,60184 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $1,814 | $156,60047 claims |
| Alkermes, Inc.Aristada | $1,906 | $71,18525 claims |
| AbbVieVraylar, Qulipta | $103 | $65,56397 claims |
| Indivior Inc.Perseris | $95 | $36,77812 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $4,554451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Saint Louis
- Aldijana SacicSaint Louis$510K
- Melinda SmithSaint Louis$13K
- Richard YakimoSaint Louis$10K
- Yevgeniya MykhaylevskaSaint Louis$9K
- Anastasia AmiramovaSaint Louis$9K
- Jessica BurichSaint Louis$8K
- Jennifer ArmstrongSaint Louis$8K
- Bonnie HuffSaint Louis$7K
- Jacqueline KirkSaint Louis$6K
- Danielle RoncoSaint Louis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.